RecruitingPhase 2NCT05963347

Go-CHOP as the Frontline Therapy for PTCL

A Phase 2 Study to Investigate the Safety, Tolerability and Anti-tumor Activity of Golidocitinib in Combination With CHOP as the Front-line Treatment for Participants With Peripheral T-cell Lymphomas (PTCL)

Sponsor

Henan Cancer Hospital

Enrollment

45 participants

Start Date

Aug 3, 2023

Study Type

INTERVENTIONAL

Conditions

Peripheral T Cell Lymphoma

Summary

This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a chemotherapy combination called Go-CHOP (which adds a drug called obinutuzumab to the standard CHOP chemotherapy regimen) as a first-line treatment for peripheral T-cell lymphoma (PTCL), an aggressive type of blood cancer that affects T-cells. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of peripheral T-cell lymphoma (PTCL) - You have not yet received treatment for PTCL - Your overall health and organ function are adequate for chemotherapy (ECOG 0–3) - You are willing to follow all study procedures **You may NOT be eligible if...** - You have already received treatment for PTCL - You have certain other serious health conditions (such as active infections, severe heart or liver problems) - You have a history of other cancers in certain situations - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.